Valuation: Moderna, Inc.

Market Cap 21.89B 19.02B 17.76B 16.3B 30.74B 2,086B 31.28B 209B 82.01B 1,040B 82.21B 80.39B 3,431B P/E 2026 *
-6.37x
P/E 2027 * -11.1x
Enterprise Value 18.54B 16.11B 15.04B 13.81B 26.04B 1,767B 26.49B 177B 69.47B 881B 69.64B 68.09B 2,907B EV / Sales 2026 *
8.8x
EV / Sales 2027 * 8.11x
Free-Float
92.7%
Yield 2026 *
-
Yield 2027 * -
1 day+3.76%
1 week+1.83%
Current month+3.34%
1 month-30.75%
3 months+19.77%
6 months+34.24%
Current year+92.10%
1 week 52.66
Extreme 52.6601
59.49
1 month 52.66
Extreme 52.6601
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
Change 5-day change 1-year change 3-year change Capi.($)
+2.34%+1.83%+104.96%-48.48% 21.89B
+0.11%+14.56%+33.73%-0.93% 76.15B
-0.67%-9.93%+19.90%+179.40% 48.89B
-4.18%+42.30%+42.30%+42.30% 47.83B
+1.01%+8.83%-52.93%-53.63% 41.37B
-1.09%+1.31%+53.37%-24.27% 29.99B
-0.77%+0.60%+53.23%+84.03% 24.23B
-0.81%-4.39%-7.53%+165.02% 19.25B
-7.35%-6.03%+61.60%+113.10% 17.14B
+0.02%-4.51%+68.23%+150.25% 15.66B
Average -0.83%+0.44%+37.69%+60.68% 34.24B
Weighted average by Cap. -0.73%+2.03%+30.79%+47.37%

Financials

2026 *2027 *
Net sales 2.11B 1.83B 1.71B 1.57B 2.96B 201B 3.01B 20.16B 7.9B 100B 7.91B 7.74B 330B 2.42B 2.11B 1.97B 1.81B 3.4B 231B 3.46B 23.19B 9.08B 115B 9.1B 8.9B 380B
Net income -3.41B -2.96B -2.76B -2.54B -4.78B -325B -4.87B -32.59B -12.76B -162B -12.79B -12.51B -534B -1.94B -1.69B -1.57B -1.44B -2.72B -185B -2.77B -18.55B -7.27B -92.17B -7.28B -7.12B -304B
Net Debt -3.35B -2.91B -2.72B -2.49B -4.7B -319B -4.78B -32.02B -12.54B -159B -12.57B -12.29B -525B -2.24B -1.95B -1.82B -1.67B -3.15B -214B -3.2B -21.43B -8.39B -106B -8.41B -8.23B -351B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
03/08/26 US$56.27 +2.65% 2,542,146
31/07/26 US$54.82 -5.35% 7,764,502
30/07/26 US$57.92 +6.29% 4,458,258
29/07/26 US$54.49 -2.36% 4,351,698
28/07/26 US$55.81 +0.31% 5,557,786
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
54.82USD
Average target price
50.84USD
Spread / Average Target
-7.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock